Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 4Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Recurrence 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Tracheal Diseases 1Stomach Neoplasms 1Smoking Cessation 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Peritoneal Neoplasms 1Pain, Postoperative 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms, Plasma Cell 1Mucopolysaccharidosis I 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lymphedema 1Lung Neoplasms 1Locally Advanced Rectal Cancer 1Liposarcoma 1

Interventions

camrelizumab 1Paclitaxel 1Combined Modality Therapy 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Esophageal Cancer × Combined Modality Therapy × Clear all
NCT05174156 2022-07-14

Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2 Unknown
50 enrolled
Gastrointestinal

Advanced Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡